Abiopharma

Omnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

New Form SCHEDULE 13G - KALA BIO, Inc. Filed: 2026-01-13 AccNo: 0001213900-26-003682 Size: 13 KB

(99% Neutral) Acadia Healthcare Company Inc (ACHC) Reports Q1 2026 Financial Results

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease

CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital

Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Oramed and Lifeward Announce Strategic Transaction

(70% Positive) Dentsply Sirona Inc (XRAY) Files Form 8-K

EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States